Business Context and Reporting Period
Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: October 14, 2024
Event: Entry into a Material Definitive Agreement regarding a senior secured convertible note and warrant offering.
Key Financial Metrics and Transaction Details
- Capital Raised: $600,000 closed (part of an up to $1.3 million offering).
- Instrument Type: Senior Secured Convertible Promissory Notes and Warrants.
- Interest Rate: 14.5% per annum (accrued interest repaid quarterly in cash).
- Original Issue Discount (OID): 5%.
- Maturity: One year from issuance.
- Warrant Coverage: 45% of the shares underlying the Notes.
- Warrant Exercise Price: $1.53 per share (125% of the closing price prior to closing).
- Shares Underlying Warrants: 286,169 shares.
- Management Participation: CEO Anatoly Dritschilo invested $237,500.
Material Changes and Terms
The Company entered into a private placement with a small group of accredited investors. Key terms include:
- Conversion Terms: Notes are convertible at a 110% premium starting three months after issuance. The conversion price is the lower of a 15% discount to the 5-day VWAP prior to closing or the price of any future offering during the term.
- Prepayment Option: The Company may prepay notes at any time with 10 days' notice for 107% of the outstanding balance.
- Ownership Limit: Conversion is restricted if it results in beneficial ownership exceeding 4.99% of outstanding shares.
- Registration Obligation: The Company must file a resale registration statement within three months of issuance.
Outlook, Risks, and Contingencies
- Follow-on Offering: The filing references a "planned follow-on offering" which may impact the conversion price of the Notes.
- Liquidity and Cash Flow: While the transaction provides immediate capital, the Company is obligated to pay accrued interest quarterly in cash, creating a recurring cash outflow.
- Dilution Risk: The combination of convertible notes and warrants (45% coverage) introduces potential dilution to existing shareholders upon conversion or exercise.
- Regulatory Status: Securities were sold under private placement exemptions (Section 4(a)(2) and Rule 506) and are not registered under the Securities Act.
Investor Verification Checklist
- Verify the total outstanding debt balance and the specific quarterly cash interest payment obligations.
- Confirm the status and timeline of the "planned follow-on offering" mentioned in the conversion price formula.
- Review the Company's current cash position to assess its ability to meet quarterly interest payments.
- Check the filing of the required resale registration statement within the three-month window.
- Monitor the 4.99% beneficial ownership limitation to understand potential conversion restrictions for investors.